Novel Stromal Cell Study in Lupus Reaches Critical Milestone
The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 with the infusion of the 81st patient - a major milestone in the pursuit of new treatment options for lupus.
The MiSLE study is a Phase II controlled trial investigating the potential of mesenchymal stromal cells (MSCs) obtained from umbilical cords as a treatment for adults with lupus. The study is exploring a novel therapeutic approach where lupus patients receive a one-time infusion of MSCs alongside their standard care to evaluate whether these cells can help alleviate symptoms and modify disease activity.
It is believed that MSCs can help correct immune system problems that contribute to lupus. If successful, this research could lead to a groundbreaking disease-modifying therapy, reducing lupus disease activity, decreasing the need for medications like steroids, and preventing long-term organ damage.
In addition to funding this research, the Lupus Foundation of America played a key role in supporting enrollment efforts, raising awareness within the lupus community and helping connect potential participants with this important study.
The trial is expected to conclude in early 2026, we eagerly anticipate the next steps in evaluating this potential breakthrough. The Lupus Foundation of America will continue to provide updates as they become available.
As a long-time leader in MSC research, the LFA was among the earliest organizations to recognize the potential of this therapy. Since 2012, with the support of generous donors, we have actively invested in pioneering studies exploring MSCs as a promising approach to lupus treatment.
Stay connected with us and sign up for our Inside Lupus Research newsletter to receive the latest research news and advancements in lupus treatment.